Back to top

Korro Bio Moves KRRO-121 Into First Human Trials, Raising the Stakes in Rare Disease RNA Editing

Korro Bio, Inc. ($KRRO) announced an update on their ongoing clinical study. The Phase 1/2 study of KRRO-121 from Korro Bio, Inc. aims to test a ne...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Korro Bio, Inc. (KRRO)